PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
Antineoplastic Combined Chemotherapy Protocols
Nitrogen Mustard Compounds
PR-104 plus sorafenib was poorly tolerated in patients with advanced HCC, possibly because of compromised clearance of PR-104A in this patient population. Thrombocytopenia mainly and neutropenia were the most clinically significant toxicities and led to discontinuation of the study. PR-104 plus sorafenib is unlikely to be suitable for development in this setting.